Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BBIO

BridgeBio Pharma Inc

Mar 17 • 04:00PM ET

33.01

Dollar change +0.04
Percentage change 0.12	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN BLUE CRSP NBIX SRPT ALNY RARE PRTA FOLD

| Held by: VTI VB IWM XBI VXF VBK IBB IWO SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.85	Insider Own	18.25%	Shs Outstand	190.04M	Perf Week	5.13%
Market Cap	6.28B	Forward P/E	-	EPS next Y	-2.77	Insider Trans	-22.19%	Shs Float	155.49M	Perf Month	4.59%
Income	-535.76M	PEG	-	EPS next Q	-0.94	Inst Own	76.13%	Short Float	14.25%	Perf Quarter	13.91%
Sales	221.90M	P/S	28.29	EPS this Y	-31.31%	Inst Trans	-3.61%	Short Ratio	7.57	Perf Half Y	22.49%
Book/sh	-7.72	P/B	-	EPS next Y	26.78%	ROA	-73.11%	Short Interest	22.16M	Perf Year	17.18%
Cash/sh	3.58	P/C	9.22	EPS next 5Y	41.46%	ROE	-	52W Range	21.62 - 39.47	Perf YTD	20.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-3.04%	ROI	-72.67%	52W High	-16.37%	Beta	1.10
Dividend TTM	-	Quick Ratio	4.67	Sales past 5Y	574.82%	Gross Margin	96.19%	52W Low	52.68%	ATR (14)	1.70
Dividend Ex-Date	-	Current Ratio	4.67	EPS Y/Y TTM	27.90%	Oper. Margin	-260.19%	RSI (14)	49.04	Volatility	3.26% 5.58%
Employees	730	Debt/Eq	-	Sales Y/Y TTM	2285.27%	Profit Margin	-241.44%	Recom	1.39	Target Price	54.67
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-45.16%	Payout	-	Rel Volume	0.62	Prev Close	32.97
Sales Surprise	91.79%	EPS Surprise	-24.98%	Sales Q/Q	237.08%	Earnings	Feb 20 BMO	Avg Volume	2.93M	Price	33.01
SMA20	-2.71%	SMA50	-1.31%	SMA200	17.90%	Trades		Volume	1,810,799	Change	0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight	$46
Mar-21-24	Resumed	Raymond James	Outperform	$45
Jan-31-24	Initiated	BMO Capital Markets	Market Perform	$37
Dec-08-23	Initiated	Wells Fargo	Overweight	$58
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy	$42
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Jul-18-23	Downgrade	Jefferies	Buy → Hold	$24 → $33
Apr-19-23	Initiated	Evercore ISI	Outperform	$40
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	SVB Leerink	Outperform	$66 → $24
Dec-27-21	Reiterated	Mizuho	Buy	$86 → $25
Sep-10-21	Upgrade	BofA Securities	Neutral → Buy	$75
May-21-21	Initiated	UBS	Buy	$80
Mar-22-21	Reiterated	Goldman	Buy	$83 → $91
Feb-22-21	Resumed	JP Morgan	Overweight	$78
Feb-09-21	Resumed	Goldman	Buy	$83
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$64 → $87

Show Previous Ratings

Mar-17-25 04:01PM	BridgeBio Announces CFO Succession (GlobeNewswire)
Mar-03-25 07:16AM	BridgeBio Oncology and Helix enter definitive merger agreement (Pharmaceutical Technology) -5.42%
Feb-28-25 06:50AM	BridgeBio oncology spinout to go public in blank-check merger (BioPharma Dive)
Feb-26-25 11:56AM	BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
02:49AM	BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt (GlobeNewswire)
04:09PM	Loading…
Feb-24-25 04:09PM	BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt (GlobeNewswire) -5.24%
Feb-23-25 03:07PM	Why BridgeBio Pharma, Inc. (BBIO) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-22-25 09:20AM	BridgeBio price target raised to $52 from $49 at Scotiabank (TipRanks)
Feb-21-25 05:13PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
Feb-20-25 08:57AM	BridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
08:55AM	BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:49AM	BridgeBio Pharma: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update (GlobeNewswire)
05:53AM	BridgeBios heart drug launch gets off to a fast start (BioPharma Dive)
Feb-13-25 04:01PM	BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025 (GlobeNewswire) +10.58%
10:48AM	Loading…
10:48AM	BridgeBio price target raised to $49 from $48 at Scotiabank (TipRanks)
Feb-12-25 06:40AM	EC grants marketing authorisation to BridgeBios ATTR-CM treatment (Pharmaceutical Technology)
Feb-11-25 09:21AM	BEYONTTRA (acoramidis), the First Near Complete TTR Stabilizer ( 90%), Approved by the European Commission to Treat ATTR-CM (GlobeNewswire)
06:38AM	Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK (BioPharma Dive)
Feb-08-25 08:46AM	Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-07-25 07:16PM	DHT, Evolve Technologies, and More Stocks See Action From Activist Investors (Barrons.com)
07:16PM	DHT, Evolv Technologies, and More Stocks See Action From Activist Investors (Barrons.com)
Feb-04-25 08:58AM	Why BridgeBio Pharma Inc. (BBIO) Crashed on Monday (Insider Monkey) +6.28%
Jan-29-25 04:00PM	Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025? (Insider Monkey)
Jan-26-25 03:07AM	Why BridgeBio Pharma (BBIO) Is Skyrocketing Now (Insider Monkey)
Jan-23-25 06:42AM	Why Is Andreas Halvorsen Bullish On BridgeBio Pharma, Inc. (BBIO) Now? (Insider Monkey)
02:00AM	BridgeBios Neil Kumar on an underdog drug launch and wooing deal-hungry investors (BioPharma Dive)
Jan-15-25 08:58AM	Is BridgeBio Pharma, Inc. (BBIO) Among Tuesdays Top Gainers? (Insider Monkey)
Jan-14-25 03:30PM	BridgeBio Pharma Stock Earns 87 RS Rating (Investor's Business Daily) +5.56%
10:00AM	Why BridgeBio Pharma (BBIO) Led the Monday Upsurge? (Insider Monkey)
04:59AM	Loading…
04:59AM	Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength? (Zacks)
Jan-13-25 06:54PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) +15.99%
04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily)
11:00AM	BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones (GlobeNewswire)
Jan-08-25 07:30AM	BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-24-24 08:40AM	BridgeBio price target raised to $50 from $45 at Evercore ISI (TipRanks)
Dec-13-24 07:18AM	Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
Dec-03-24 08:00AM	Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology (GlobeNewswire)
Nov-26-24 09:10AM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
06:50AM	BridgeBio price target raised to $45 from $42 at BofA (TipRanks)
Nov-25-24 04:16PM	BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug (Investor's Business Daily) +16.10%
09:40AM	BridgeBio Soars After Drug Gets Nod in Rare Heart Condition (Bloomberg)
09:03AM	FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market (Benzinga)
04:38AM	FDA approves BridgeBios Attruby for ATTR-CM treatment (Pharmaceutical Technology)
Nov-22-24 07:11PM	Attruby (acoramidis), a Near Complete TTR Stabilizer ( 90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients (GlobeNewswire)
02:16PM	BridgeBio heart drug approved by FDA, setting up battle with Pfizer (BioPharma Dive)
Nov-21-24 05:43PM	Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-19-24 02:44PM	BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market (Benzinga)
Nov-18-24 11:15AM	Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months (GlobeNewswire) -5.78%
05:30AM	BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia (GlobeNewswire)
Nov-12-24 08:39PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) -5.74%
08:45AM	BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:40AM	BridgeBio Pharma: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-05-24 07:30AM	BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management (GlobeNewswire)
Oct-31-24 10:01AM	BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-24-24 07:30AM	BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 (GlobeNewswire)
Oct-04-24 05:17AM	3 Top Stocks That Could Still Rocket Higher in 2024 (Motley Fool)
Oct-03-24 07:30AM	BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions (GlobeNewswire)
Oct-01-24 05:00AM	5 FDA decisions to watch in the fourth quarter (BioPharma Dive)
Sep-30-24 01:17PM	BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease (Benzinga)
12:09PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:30AM	BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) (GlobeNewswire)
Sep-27-24 06:00PM	BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events (GlobeNewswire)
Sep-17-24 07:30AM	BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA (GlobeNewswire)
Sep-12-24 01:01PM	The Brawl Taking Shape Over Pfizers Multibillion-Dollar Heart Monopoly (The Wall Street Journal)
Sep-11-24 01:44PM	BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition (Benzinga) -6.67%
07:35AM	BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine (BioPharma Dive)
Sep-10-24 04:45PM	BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program (GlobeNewswire)
04:45PM	BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
Sep-06-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-24 04:03PM	Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug (The Wall Street Journal) +13.12%
01:10PM	Why Is BridgeBio Pharma Stock Trading Higher On Friday? (Benzinga)
10:50AM	BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension (GlobeNewswire)
Aug-29-24 07:30AM	BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 (GlobeNewswire)
Aug-28-24 07:30AM	BridgeBio Pharma to Participate in September Investor Events (GlobeNewswire)
Aug-26-24 07:30AM	BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence (GlobeNewswire)
Aug-21-24 07:43AM	BridgeBio sends rare disease drugs to new company (BioPharma Dive)
Aug-19-24 07:30AM	BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia (GlobeNewswire)
Aug-08-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-01-24 08:40AM	BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:41AM	BridgeBio Pharma: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-23-24 07:30AM	BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer (GlobeNewswire)
Jul-05-24 04:31PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-27-24 02:21PM	BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy? (Insider Monkey) +6.96%
Jun-26-24 10:12PM	10 Best Healthcare Stocks to Buy Under $50 (Insider Monkey)
Jun-18-24 07:30AM	BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) (GlobeNewswire)
Jun-10-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-24 07:30AM	BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
Jun-05-24 01:35PM	The 3 Best Biotech Stocks to Buy in June 2024 (InvestorPlace)
Jun-04-24 04:19PM	BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug (Investor's Business Daily) -6.38%
10:15AM	BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results (Investor's Business Daily)
08:00AM	BridgeBio data show sustained benefit for achondroplasia drug (BioPharma Dive)
07:30AM	BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia (GlobeNewswire)
Jun-03-24 04:01PM	BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 (GlobeNewswire)
May-29-24 04:01PM	Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-24-24 07:30AM	BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting (GlobeNewswire)
May-15-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Valantine Hannah	Director	Mar 06 '25	Option Exercise	16.75	12,875	215,656	14,639	Mar 10 04:43 PM
Valantine Hannah	Director	Mar 06 '25	Sale	32.58	12,875	419,500	1,764	Mar 10 04:43 PM
KKR Genetic Disorder L.P.	10% Owner	Mar 05 '25	Sale	32.96	6,000,000	197,760,000	19,260,971	Mar 07 06:09 PM
HANNAH A VALANTINE	Director	Mar 06 '25	Proposed Sale	32.58	12,875	419,500		Mar 06 04:06 PM
KKR Genetic Disorder L.P.	Affiliate	Mar 05 '25	Proposed Sale	34.97	6,000,000	209,820,000		Mar 05 09:09 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Option Exercise	17.00	8,500	144,500	110,964	Feb 27 05:36 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Sale	33.19	8,500	282,115	102,464	Feb 27 05:36 PM
Kumar Neil	Chief Executive Officer	Feb 25 '25	Sale	33.57	75,000	2,517,971	5,023,447	Feb 27 05:12 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Feb 25 '25	Proposed Sale	36.25	300,000	10,875,000		Feb 25 04:35 PM
BRIAN STEPHENSON	Officer	Feb 25 '25	Proposed Sale	36.25	34,000	1,232,500		Feb 25 04:34 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Feb 19 '25	Sale	36.16	4,148	149,973	102,464	Feb 19 08:50 PM
Kumar Neil	Chief Executive Officer	Feb 19 '25	Sale	36.14	31,543	1,140,024	211,718	Feb 19 08:48 PM
NEIL KUMAR	Director	Feb 19 '25	Proposed Sale	35.49	31,543	1,119,461		Feb 19 04:31 PM
BRIAN STEPHENSON	Officer	Feb 19 '25	Proposed Sale	35.49	4,148	147,213		Feb 19 04:31 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 31 '25	Proposed Sale	34.90	3,065,616	106,989,998		Jan 31 07:18 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 31 '25	Sale	34.90	3,065,616	106,989,998	22,055,375	Jan 31 07:18 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Jan 28 '25	Option Exercise	17.00	68,000	1,156,000	161,758	Jan 30 06:31 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Jan 28 '25	Sale	36.29	68,000	2,467,761	93,758	Jan 30 06:31 PM
Kumar Neil	Chief Executive Officer	Jan 28 '25	Sale	36.29	326,932	11,863,381	5,371,515	Jan 30 06:29 PM
Kumar Neil	Chief Executive Officer	Jan 29 '25	Sale	36.35	273,068	9,925,269	5,098,447	Jan 30 06:29 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Jan 28 '25	Proposed Sale	36.67	600,000	22,002,000		Jan 28 04:18 PM
BRIAN STEPHENSON	Officer	Jan 28 '25	Proposed Sale	36.67	68,000	2,493,560		Jan 28 04:18 PM
Satvat Ali J.	Director	Dec 30 '24	Option Exercise	16.22	159,404	2,585,134	159,404	Dec 31 05:52 PM
Kumar Neil	Chief Executive Officer	Nov 19 '24	Sale	22.41	27,389	613,826	4,897,443	Nov 20 08:00 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Nov 19 '24	Sale	22.41	4,156	93,137	93,758	Nov 20 07:57 PM
BRIAN STEPHENSON	Officer	Nov 19 '24	Proposed Sale	22.35	4,156	92,887		Nov 19 04:28 PM
NEIL KUMAR	Director	Nov 19 '24	Proposed Sale	22.35	27,389	612,144		Nov 19 04:24 PM
KKR Genetic Disorder L.P.	10% Owner	Sep 13 '24	Sale	25.75	5,800,000	149,350,000	25,260,971	Sep 17 06:44 PM
KKR Genetic Disorder L.P.	Affiliate	Sep 13 '24	Proposed Sale	26.95	5,800,000	156,310,000		Sep 13 05:04 PM
Kumar Neil	Chief Executive Officer	Aug 19 '24	Sale	24.69	27,389	676,256	4,897,443	Aug 20 06:31 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Aug 19 '24	Sale	24.69	4,155	102,590	85,192	Aug 20 06:27 PM
BRIAN STEPHENSON	Officer	Aug 19 '24	Proposed Sale	24.40	4,155	101,382		Aug 19 04:29 PM
NEIL KUMAR	Director	Aug 19 '24	Proposed Sale	24.40	27,389	668,292		Aug 19 04:27 PM
Scott Randal W.	Director	Jun 04 '24	Sale	31.30	1,500	46,950	4,000	Jun 05 04:53 PM
Scott Randal W.	Director	Jun 03 '24	Sale	28.84	1,000	28,843	5,500	Jun 05 04:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BBIO

BridgeBio Pharma Inc

Upgrade your FINVIZ experience